Nipah Virus: Malappuram girl dies, Centre mulls sending team to Kerala to implement public health measures
The patient, hailing from Chettiyarangadi in Malappuram, succumbed after receiving treatment at a private hospital in Kozhikode district.
The preliminary tests indicated Nipah and the infection was subsequently confirmed by the National Institute of Virology (NIV) in Pune after sample examination, the PTI report said.
On Friday, local authorities in Palakkad district issued a strong warning to the public and health workers to remain extremely vigilant after a 38-year-old woman from Thachanattukara was also tested positive for Nipah.
Health authorities in Malappuram initiated surveillance in 20 wards in panchayats such as Makkaraparamba, Kuruva, Kootilangadi, and Mankada, an official statement said on Saturday.
The objective was to identify the source of the disease and strengthen household-based awareness, it added.
A total of 65 teams visited 1,655 houses and found no one with symptoms of Nipah during the survey, the statement also said.
The Central Surveillance Unit of the Integrated Disease Surveillance Programme (IDSP), NCDC, is in close contact with the state unit and is actively monitoring the situation.
The State Control Room has been activated for coordinating the various containment activities.
The public health response is guided by the Kerala State NiVD guidelines for surveillance, diagnosis, treatment, prevention and control.
Meanwhile, Kerala Health Minister Veena George held a high-level meeting in Thiruvananthapuram to review the situation.
She informed that 425 people are on the Nipah contact list, with 228 in Malappuram, 110 in Palakkad, and 87 in Kozhikode.
Of them, five people are admitted to the intensive care unit (ICU), and the test result of another person in the contact list turned negative for the infection, the minister's office said in a statement.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
2 hours ago
- Hindustan Times
Naveen Patnaik returns to Odisha after 21 days after spine surgery in Mumbai
Biju Janata Dal (BJD) president Naveen Patnaik on Saturday returned to Bhubaneswar after fully recovering from his spine surgery for cervical arthritis in Mumbai. Patnaik had left for Mumbai on June 20 and underwent spine surgery for cervical arthritis.(PTI File) Patnaik's special flight landed at the Biju Patnaik International Airport at about 2 pm. He returned to Odisha after 21 days, said BJD senior vice president Debi Prasad Mishra. The former five-time chief minister of Odisha was accorded a ceremonial welcome by the party men and women, who gathered at the airport since morning. The Jai Jagannath slogan rented the air as Patnaik stepped out of the airport. Holding placards and BJD flags, thousands of people stood on both sides of the road leading from the airport to Naveen Niwas, the residence of Patnaik, to welcome and greet their leader. He waved to the people at the airport. Patnaik, the Leader of the Opposition in Odisha Assembly, had left for Mumbai on June 20 and underwent spine surgery for cervical arthritis at Kokilaben Dhirubhai Ambani Hospital in Mumbai on June 22. He was shifted to a private room from the ICU after being kept under observation for two days and was discharged from the hospital on July 7. The surgery was conducted by Dr S Rajasekaran, an orthopaedic surgeon and chairman of Ganga Medical Center and Hospitals in Coimbatore. In Patnaik's absence, the BJD's 15-member committee led by vice-president Debi Mishra was looking after party affairs in the state.
News18
3 hours ago
- News18
New Covid Variant XFG Explained: Symptoms, Spread & Safety Tips You Need To Know
Last Updated: Symptoms mirror Omicron's, that is, fever, cough, fatigue, sore throat, and muscle aches. Though India's Covid response offers a foundation, but XFG demands targeted strategies As India navigates a post-Covid world, a new Omicron subvariant, XFG ('Stratus"), is raising concerns with its rapid spread and immune-evasive traits. First detected in Canada, XFG has reached 38 countries, including India, where it accounts for a growing share of cases. With India's active Covid-19 cases at 7,000 as of June 2025, per the Union Health Ministry, let's examine XFG's characteristics, India-specific data, and how the nation can prepare for this and future pandemics, drawing lessons from long Covid. What Is The XFG Variant? XFG, a recombinant subvariant of Omicron, emerges from the fusion of LF.7 and LP.8.1.2 strains, formed when two variants infect a person simultaneously, mixing genetic material. A Lancet study highlights four key spike protein mutations—His445Arg, Asn487Asp, Gln493Glu, and Thr572Ile—enabling 'strong immune evasion," allowing XFG to bypass antibodies from prior infections or vaccines. Globally, XFG accounts for 22.7% of sequenced cases as of June 2025, up from 7.4% a month earlier, per GISAID (Global Initiative on Sharing All Influenza Data), and may soon dominate over NB.1.8.1 ('Nimbus"), per The Conversation. In India, it's the dominant strain in Madhya Pradesh, with 63.6% of sequenced samples, per AIIMS Bhopal. Symptoms mirror Omicron's, that is, fever, cough, fatigue, sore throat, and muscle aches. However, XFG uniquely causes hoarseness—a scratchy or raspy voice—reported by doctors as a key marker, per Everyday Health. Unlike JN.1, which caused low-grade fever and digestive issues, XFG's symptoms are mild to moderate, with no evidence of increased severity or hospitalisation rates, per WHO. Current vaccines, targeting JN.1, remain effective against severe disease, and antivirals like Paxlovid and remdesivir work, per Time. How Many XFG Cases Have India Reported? India has reported 206 XFG cases as of June 11, per INSACOG, with Maharashtra leading at 89 cases, followed by West Bengal (49), Tamil Nadu (16), Kerala (15), Gujarat (11), and Andhra Pradesh, Madhya Pradesh (6 each), Odisha (4), Puducherry (3), Delhi, Rajasthan, and Punjab (2 each), and Telangana and Haryana (1 each), per The Hindu. Of these, 159 cases were detected in May, with two each in April and June, indicating a rapid rise. India's active Covid-19 cases reached 7,000 by June 11, with Kerala reporting the highest active cases (2,200), followed by Gujarat (1,223) and Delhi (757). A 2024 ICMR survey notes 66% of respiratory viral infections in India are Covid-related, but hospitalisations remain low, News18 reported. AIIMS Bhopal's genomic analysis of 44 samples from May-June found XFG dominant in 28 (63.6%), with no NB.1.8.1 detected in Madhya Pradesh, highlighting regional variation. Dr Rajiv Behl, ICMR Director General, stresses XFG's low severity but urges vigilance for vulnerable groups—those over 70 or with comorbidities. Why XFG Matters To India India's 1.4 billion population and $3 trillion economy face significant risks from new variants. Long Covid, affecting 7% of India's 44 million Covid cases (3 million people), costs 1% of GDP annually, per a 2024 NITI Aayog estimate, with 40% reporting fatigue and 25% brain fog. XFG's immune evasion could exacerbate this. Rural areas, with only 10% of health centres offering post-Covid care, face worse outcomes, per The Indian Express. A 2024 Times of India poll shows only 25% of Indians know about long Covid, limiting XFG awareness. Vaccine hesitancy, at 30% in rural India, and low Omicron-specific booster uptake (18%) weaken defences, per ICMR 2024. With 74 Covid deaths in 2025, mostly among the elderly and immunocompromised, XFG's spread threatens vulnerable groups. How India Should Prepare India's Covid response—2.2 billion vaccine doses by 2025—offers a foundation, but XFG demands targeted strategies: Enhanced Genomic Surveillance: INSACOG's 54 labs must expand sequencing, as only 0.1% of cases are sequenced, per The Hindu. AIIMS Bhopal's model, detecting XFG in 63.6% of samples, shows the value of regional labs. Scaling Truenat and RT-PCR testing to 80% of health centers, especially rural ones, could detect variants early, per Dr Balram Bhargava, a renowned cardiologist and public health leader. Vaccination & Boosters: Only 18% of Indians have Omicron-specific boosters. A 2025 campaign targeting 50% booster coverage, especially for those over 70, could cut severe cases by 30%, per WHO. Mobile vaccination units, successful in 2021, should reach rural areas. Hospital Preparedness: Only 50% of health centres have ventilators, and 30% lack oxygen, per a 2024 MoHFW report. The Centre's 2025 mock drills must ensure 75% of 1.5 lakh centers have isolation beds and antivirals, costing Rs 5,000 crore. Telemedicine, used by 15% of urban Indians, can expand to rural areas. Masking and Ventilation: XFG's spread in crowded spaces, like Mumbai's trains, requires masks and improved ventilation. A 2023 Singapore study cut transmission by 20% with air purifiers. India's public buildings need similar upgrades. Get breaking news, in-depth analysis, and expert perspectives on everything from politics to crime and society. Stay informed with the latest India news only on News18. Download the News18 App to stay updated! tags : covid symptoms Long COVID omicron view comments Location : New Delhi, India, India First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
The Print
3 hours ago
- The Print
Facial, speech problems among after-effects of mucormycosis post recovery: ICMR study
Published last month in Clinical Microbiology and Infection, a leading microbiology journal, the study found that 14.7 per cent of 686 hospitalised mucormycosis patients died within a year, with most deaths occurring during initial hospitalisation. There was an uptick in cases of mucormycosis, a rare infection also known as 'Black Fungus', during the COVID-19 pandemic. New Delhi, Jul 12 (PTI) People who suffered from mucormycosis and recovered continue to battle long-term health effects of the fungal infection, such as facial disfigurement and speech difficulty, found an ICMR study. Critical predictors of poor survival included involvement of the brain or eyes, intensive care admission, poor glycaemic control, and comorbid conditions. Conversely, patients who received both surgical treatment and combination antifungal therapy (particularly Amphotericin-B formulations with Posaconazole) had significantly higher survival rates, said Dr Rizwan Suliankatchi Abdulkader, from ICMR's National Institute of Epidemiology (NIE), the lead author of the study. 'But survivors often faced disfigurement and psychological distress, with more than 70 per cent reporting at least one clinical sequela (complication or disability) and a substantial proportion experiencing loss of employment,' Rizwan said. 'These are not abstract complications. Facial disfigurement, impaired speech, anxiety, and loss of livelihood are lived realities for many survivors. It is time for India to move beyond life-saving interventions and focus on life-restoring systems of care, including mental health support and rehabilitation,' he said. Led by Rizwan and the All-India Mucormycosis Consortium, the study assessed survival, treatment outcomes, and post-recovery quality of life among hospitalised patients in India. This large-scale study, covering 686 patients from 26 tertiary hospitals across the country, is the first of its kind to offer long-term, prospective data on this critical public health concern. As a part of the study, 686 patients who had contracted mucormycosis between March and July 2021 were followed up for one year. Of the 686, 80 per cent (549) also had COVID-19. The prevalence of mucormycosis varies significantly, from 0.01 to 2 cases per million in developed countries to 140 cases per million in India and similar nations, with incidence approximately 80 times higher in India. Despite advances in medical care, mucormycosis remains a highly lethal and debilitating condition. 'This study reinforces the pressing need to ensure access to timely diagnosis, surgical interventions, and combination antifungal therapy in all parts of India,' said Dr Manoj Murhekar, Director of Chennai-based ICMR-NIE. 'We cannot overstate how essential high-quality, multidisciplinary care is for patients battling mucormycosis, especially given the irreversible complications they face if treatment is delayed,' said Murhekar, a senior author of the study. Spanning the length and breadth of India, the study involved institutions from nearly every region, capturing a diverse and realistic picture of mucormycosis management in both urban and rural populations. Rizwan stressed, 'This is not just a story of numbers. Behind every data point is a person who struggled with pain, disfigurement, and long-term disability. Our duty as clinicians and public health professionals is to reduce not just mortality but also the suffering that comes with survival. 'India has a disproportionately high burden of this disease. Our health systems must be better prepared.' The research comes at a time when India is still grappling with the long-term fallout of the COVID-19 pandemic, during which mucormycosis surged dramatically. As the global community turns its attention to pandemic preparedness and health system resilience, the study serves as a sobering reminder of the challenges posed by neglected fungal diseases. 'We hope our findings will serve as a call to action for policymakers, hospital administrators, and clinicians. Mucormycosis is not just a complication of COVID-19. It is a disease that demands long-term clinical attention, public health surveillance, and above all, compassion in care,' Rizwan said. PTI PLB SKY SKY This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
